Archives
- 2025-12
- 2025-11
- 2025-10
- 2025-09
- 2025-03
- 2025-02
- 2025-01
- 2024-12
- 2024-11
- 2024-10
- 2024-09
- 2024-08
- 2024-07
- 2024-06
- 2024-05
- 2024-04
- 2024-03
- 2024-02
- 2024-01
- 2023-12
- 2023-11
- 2023-10
- 2023-09
- 2023-08
- 2023-07
- 2023-06
- 2023-05
- 2023-04
- 2023-03
- 2023-02
- 2023-01
- 2022-12
- 2022-11
- 2022-10
- 2022-09
- 2022-08
- 2022-07
- 2022-06
- 2022-05
- 2022-04
- 2022-03
- 2022-02
- 2022-01
- 2021-12
- 2021-11
- 2021-10
- 2021-09
- 2021-08
- 2021-07
- 2021-06
- 2021-05
- 2021-04
- 2021-03
- 2021-02
- 2021-01
- 2020-12
- 2020-11
- 2020-10
- 2020-09
- 2020-08
- 2020-07
- 2020-06
- 2020-05
- 2020-04
- 2020-03
- 2020-02
- 2020-01
- 2019-12
- 2019-11
- 2019-10
- 2019-09
- 2019-08
- 2019-07
- 2019-06
- 2018-07
-
We analyzed whether HaCaT cells treated with PLD can alter
2021-01-05

We analyzed whether HaCaT cdk9 inhibitor receptor treated with PLD can alter the expression of genes involved in DNA damage response. Key DNA damage cues activate the sensory DNA-PK/ATM/ATR kinases, which relay two parallel cascades that ultimately serve to inactivate the Cyclin B-cdc2 complex. The
-
These reactions are used to account for variations in protei
2021-01-05

These reactions are used to account for variations in protein solubility or vesicle recovery. For example, with DGKθ we have found it necessary to maintain the purified enzyme in a solution of 0.01% DDM (DGK-D dilution buffer) in the control reaction to prevent enzyme loss due to aggregation or adhe
-
To understand the behavior of enzymes in ILs
2021-01-05

To understand the behavior of enzymes in ILs at a molecular level, it is first desirable to dissolve enzymes in the solvents. For soluble catalysts, there are many relatively simple spectroscopic and other techniques for obtaining accurate information at a molecular level. Parker et al. [9] reported
-
br Acknowledgments This work was supported by
2021-01-05

Acknowledgments This work was supported by Grants from the National Research Foundation (2010-0000782) and the National Center for GM Crops (PJ008152) of the Next Generation BioGreen 21 Program funded by the Rural Development Administration, Republic of Korea, to W.T.K. Introduction Ubiquityl
-
Another pathway that requires proper
2021-01-05

Another pathway that requires proper DUB recruitment is the DNA damage response (DDR). After ultraviolet (UV)-induced DNA damage, monoubiquitylated proliferating cell nuclear antigen (PCNA) mediates signaling that leads to repair. The DUB complex USP1/USP1-associated factor 1 (UAF1) deubiquitylates
-
br Conclusions br Acknowledgement Grant support Ministry
2021-01-05

Conclusions Acknowledgement Grant support: Ministry of Health (n. of grant: RBAP10447J_004 to N. Baldini), Italian Association for Cancer Research (n. of grant: 11426 to N. Baldini). Introduction Ewing sarcomas (ES) and primitive neuroectodermal tumors (PNET) are related childhood tumors.
-
br Other pathways involved in the preventive and therapeutic
2021-01-05

Other pathways involved in the preventive and therapeutic potential of flavonoids in neurodegenerative diseases Rather than the induction of MAPK/ERK pathway, flavonoids actively modulate other critical intracellular neuronal survival and death protein kinases pathways, more importantly PI3K/Akt,
-
br Author Contributions Statement br Conflicts of interest b
2021-01-04

Author Contributions Statement Conflicts of interest Acknowledgments We thank T. Ishii, H. Inaba, and S. Nakamura (Department of Cell Biology, TMDU) for kindly gifting BACCS and technical assistance; S. Kaneko, Y. Ishida, and R. Usumi (Department of Orthodontic Science, TMDU) for experiment
-
We demonstrated that cells expressing less
2021-01-04

We demonstrated that ruthenium red receptor expressing less DHODH were less sensitive to DHODH inhibitors regardless of their oncogenic status. Based on the proliferation speed of cells, Kant et al. (1989), showed that slow-growing squamous cell carcinoma was more sensitive to BQR than fast-growing
-
br Hypothesis on DDR protective mode of action
2021-01-04

Hypothesis on DDR1 protective mode of action The documented protective role of DDR1 is quite impressive, demonstrated using different preclinical models (immunologic [46,54,58], obstructive [45], and hypertensive [50]) with different intervention paradigms: genetic ablation [45,50,58,72], silenci
-
Electroencephalographs at onset ranged from hypsarrhythmia
2021-01-04

Electroencephalographs at onset ranged from hypsarrhythmia to mild abnormalities but more abnormalities in background rhythms and epileptiform activity develop over time.15, 17, 19, 48, 52, 54, 55 Early mild abnormalities that sometimes precede a diffuse encephalopathy included focal delta slowing i
-
Phylogenetically three related CXC chemokines are classified
2021-01-04

Phylogenetically three related CXC chemokines are classified as the possible ligands for the teleost CXCR1 and CXCR2. They are referred to as CXCL8_L1 (CXCL8/IL-8/CXCa), CXCL8_L2 (CXCc) and CXCL8_L3 (Alejo and Tafalla, 2011, Chen et al., 2013, Laing et al., 2002, Laing and Secombes, 2004, Nomiyama e
-
multidrug resistance transporter The best preserved individu
2021-01-04

The best preserved individuals were selected for isotope analysis of diet (Table 2). These represent 21 individuals including four subadults: two young children aged between 1.5 and 2.5 years old, one child between 7 and 11 years old and one adolescent (12–16 years old), and 17 adults including six
-
Moreover the vibrational contributions provide
2021-01-04

Moreover, the vibrational contributions provide a plausible explanation for the missing X′ peaks in the experimental PES for the Er and Tm complexes. The current SO-MCQDPT2 (Fig. 1(k) and (l)) and MCQDPT2 II (Fig. 2(k) and (l)) calculations suggest the appearance of peak splittings for these complex
-
br Authors contribution br Disclosure statement
2020-12-31

Authors contribution Disclosure statement Acknowledgements This study has received funding from the Italian Ministry of University and Research (PRIN 2015, grant number 2015373Z39_008) and from the Innovative Medicines Initiative 2 Joint Undertaking under grant agreement No 115797 (INNODIA)
14742 records 698/983 page Previous Next First page 上5页 696697698699700 下5页 Last page